期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 18, 期 3, 页码 348-371出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2011.12.519
关键词
Hematopoietic cell transplantation; Allogeneic; Autologous; Late complications; Screening; Prevention
资金
- Public Health Service from National Cancer Institute (NCI) [U24-CA76518]
- National Heart, Lung and Blood Institute (NEILBI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- NHLBI [5U-01HL069294]
- NCI
- Office of Naval Research [N00014-06-1-0704, N00014-08-1-0058]
- AABB
- Allos, Inc.
- Amgen, Inc.
- Health Resources and Services Administration (HRSA/DHHS) [HHSH234200637015C]
- Grants-in-Aid for Scientific Research [23791077] Funding Source: KAKEN
Advances in hematopoietic cell transplantation (HCT) technology and supportive care techniques have led to improvements in long-term survival after HCT. Emerging indications for transplantation, introduction of newer graft sources (eg, umbilical cord blood) and transplantation of older patients using less intense conditioning regimens have also contributed to an increase in the number of HCT survivors. These survivors are at risk for developing late complications secondary to pre-, peri-, and posttransplantation exposures and risk factors. Guidelines for screening and preventive practices for HCT survivors were published in 2006. An international group of transplantation experts was convened in 2011 to review contemporary literature and update the recommendations while considering the changing practice of transplantation and international applicability of these guidelines. This review provides the updated recommendations for screening and preventive practices for pediatric and adult survivors of autologous and allogeneic HCT. Biol Blood Marrow Transplant 18: 348-371 (2012) (C) 2012 Published by Elsevier Inc. on behalf of the American Society for Blood and Marrow Transplantation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据